CompletedNot Applicable

Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.

Netherlands123 participantsStarted 2013-08

Plain-language summary

The aim of this trial is to identify biomarkers and genetic predisposition for the development of immune checkpoint related colitis.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Patients with melanoma who will be treated with immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab)
✓. Signed written informed consent.
✓. Able to comply with the protocol.

Genetic predisposition for immunotherapy-induced colitis

Timeframe: 1 week

NCT IDNCT02600143

SponsorUniversity Medical Center Groningen

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-04